These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35967350)

  • 21. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern.
    Schwarze M; Krizsan A; Brakel A; Pohl F; Volke D; Hoffmann R
    Front Immunol; 2022; 13():915034. PubMed ID: 35784285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2.
    Williams E; Colson J; Valiathan R; Carreño JM; Krammer F; Hoffer M; Pallikkuth S; Pahwa S; Andrews D
    Vaccine; 2022 Sep; 40(41):5868-5872. PubMed ID: 36088193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
    Maeda R; Fujita J; Konishi Y; Kazuma Y; Yamazaki H; Anzai I; Watanabe T; Yamaguchi K; Kasai K; Nagata K; Yamaoka Y; Miyakawa K; Ryo A; Shirakawa K; Sato K; Makino F; Matsuura Y; Inoue T; Imura A; Namba K; Takaori-Kondo A
    Commun Biol; 2022 Jul; 5(1):669. PubMed ID: 35794202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Huang D; Tibbitts T; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2022 Mar; 13(1):1699. PubMed ID: 35361754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
    Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
    PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
    Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
    J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study.
    Nag A; Banerjee R; Paul S; Kundu R
    Comput Biol Med; 2022 Jul; 146():105552. PubMed ID: 35508082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities.
    Hu S; Wu C; Wu X; Ma X; Shu C; Chen Q; Zheng A; Yang H; Lu J; Du P; Gao GF; Wang Q
    Sci Bull (Beijing); 2023 Dec; 68(23):3003-3012. PubMed ID: 37919162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.